Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Gulo who wrote (10680)	2/27/2004 11:21:00 AM
From: Biomaven	Read Replies (1) \| Respond to of 52153

Gulo, XIAP pathway is very important in my opinion. I haven't followed HBY at all myself. There have been problems convincingly demonstrating antisense in practice - it's a great idea in theory, but there have been issues delivering the drug to the target in a reliable and sustainable manner. I guess GNTA's Genasense is furthest along. Other companies involved in antisense are ISIS and AVII. The "leading edge" has generally moved from antisense to siRNA. Doesn't mean an antisense drug may not be successful. Peter